SecBot SecBot
SECBOTREPLAY Home › Report › BNTX

BNTX · BioNTech reported full-year 2025 revenues of €2.87 billion, up 4.3%…

BioNTech SE · PRESS-RELEASE filed Mar 10, 2026 at 06:45 ET

At the news

BEARISHIMPACT 7/10

PRESS-RELEASE filed Mar 10, 2026 at 06:45 ET

BioNTech reported full-year 2025 revenues of €2.87 billion, up 4.3% YoY, but posted a net loss of €1.14 billion (€4.70 diluted loss per share), widening from a €665.3 million loss in 2024. The quarterly revenue declined 23.7% due to lower COVID-19 vaccine demand, and the company issued 2026 revenue guidance of €2.0–2.3 billion, signaling a further decline. Despite a strong cash position of €17.2 billion, the outlook reflects continued transition from pandemic-era revenues to oncology-focused R&D, with multiple late-stage readouts expected in 2026.

  • Full-year 2025 revenue: €2.87 billion (up 4.3% YoY), driven by BMS collaboration revenue in Q3
  • Q4 2025 revenue: €907.4 million, down 23.7% YoY due to lower COVID-19 vaccine demand
  • Full-year 2025 net loss: €1.14 billion, compared to €665.3 million loss in 2024
  • 2026 revenue guidance: €2.0–2.3 billion, implying 19.7%–20.8% YoY decline at midpoint

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access